Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previou...
<![CDATA[Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day]]>
Moderna, Inc. (MRNA) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results
Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus
Moderna’s Cancer Vaccine: A Medical Breakthrough, a Wall Street Meltdown, and a New Era in Cancer Treatment
Moderna’s Cancer Vaccine: A Medical Breakthrough, a Wall Street Meltdown, and a New Era in Cancer Treatment Anonymous (not verified) Sat, 10/24/2026 - 13:17 pharmagather...
This week in charts: Moderna’s massive stock run
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at Moderna
Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be revealed this weekend.
The Merck/Moderna Results
The Merck/Moderna Results Anonymous (not verified) Fri, 10/23/2026 - 13:17 pharmagather item url The Merck/Moderna Results pharmagather...
Santé Canada autorise deux vaccins à ARNm de Moderna : un vaccin contre la grippe et un vaccin combiné contre la grippe...
Le Canada est le premier pays à autoriser à la fois le vaccin à ARNm de Moderna contre la grippe saisonnière, mFLUSIVA®, et son vaccin combiné contre la grippe et la COVID-19, mCOF...
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027
Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.
Moderna: 3 Key Takeaways for Long-Term Investors
Its proprietary software is built into the cancer drug itself, creating a front-end design moat that rivals may struggle to replicate.
Moderna CEO eyes China partnerships despite geopolitical tensions
Northwestern's IP License With Feds Doesn't Protect Moderna
Moderna Inc. has lost its attempt to escape Northwestern University's patent infringement suit over COVID-19 vaccinations by citing the university's patent licensing agreement with...
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
It was a head-turning headline. Here's why the market was buzzing.
Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®
Moderna (MRNA) Stock Forecast & Predictions for 2026, 2027, 2028–2030 and Beyond
Moderna (#MRNA) is a biotechnology company that has gained recognition for its innovative mRNA technology and its role in the development of a vaccine for the novel coronavirus dis...
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sel...
Moderna sheds about $24 billion as cancer vaccine data triggers ’sell-the-news’ retreat
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.